All In Biotech

Drug Trial Radar · NCT03275922

Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy And Safety Of Zolmitriptan Nasal Spray For The Treatment Of Acute Migraine In Subjects Ages 6 To 11 Years, With An Open-Label Extension

Last checked: Nov 20, 2026Latest source record: Jan 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 374 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

374

Actual

Start

Nov 27, 2017

Primary completion

Jul 2, 2020

Study completion Sep 28, 2020

Sponsor

Lead sponsor
Impax Laboratories, LLCIndustry
Sponsor type
Industry
Collaborators
AstraZeneca
First posted
Sep 8, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of zolmitriptan nasal spray (ZNS) in the acute treatment of migraine headache in subjects ages 6 to 11 years. Part 1: Approximately 20 weeks (includes screening and double-blind treatment). * Screening will be performed based on the inclusion exclusion criteria specified in the study protocol. * Randomize approximately 288 subjects into the double-blind crossover phase. Part 2: Approximately 100 subjects who complete the double-blind crossover phase will enter part 2, a 6 month open-label safety extension (OLE). Efficacy will be evaluated in the double-blind part of the trial. Safety will be evaluated in both the double-blind and the OLE.

Conditions

  • Migraine

Interventions

  • Placebo ZNSDrug

    Placebo Zolmitriptan Nasal Spray

  • ZNSDrug

    Zolmitriptan Nasal Spray

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pain-free status at 2 hours post treatmentTime frame: 2 hours post-dose

Locations

47 sites in 1 country. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital (149)

    Phoenix, Arizona

  • Arkansas Children's Hospital (109)

    Little Rock, Arkansas

  • Advanced Research Center, Inc (134)

    Anaheim, California

  • Sierra Medical Research (124)

    Fresno, California

  • Shailesh M. Asaikar, MD. Inc. DBA Child and Adolescent Neurology Consultatns (119)

    Sacramento, California

  • Children's Hospital Colorado (154)

    Aurora, Colorado

  • Blue Sky Neurology (106)

    Englewood, Colorado

  • IMMUNOe Research Centers (150)

    Thornton, Colorado

  • Ki Health Partners, LLC dba New England INstitute for Clinical Research (128)

    Stamford, Connecticut

  • Children's National Health System (141)

    Washington D.C., District of Columbia

  • NW Florida Clinical Research Group, LLC (122)

    Gulf Breeze, Florida

  • Clinical Neuroscience Solutions, Inc. (127)

    Jacksonville, Florida

  • Axcess Medical Research (126)

    Loxahatchee Groves, Florida

  • Biotech Pharmaceutical Group (138)

    Miami, Florida

  • Sanitas Medical and Dental Institute/dba Sanitas Research, LLC (142)

    Miami, Florida

  • Laszlo J. Mate, M.D., P.A. (153)

    North Palm Beach, Florida

  • Clincial Neuroscience Solutions, Inc. (136)

    Orlando, Florida

  • Pediatric Neurology, PA (125)

    Orlando, Florida

  • East Florida Research (143)

    Port Saint Lucie, Florida

  • Pedatric Epilepsy & Neurology Specialists (157)

    Tampa, Florida

  • Premiere Research Institute @ Palm Beach Neurology, PA (105)

    West Palm Beach, Florida

  • Clinical Integrative Research Center of Atlanta (121)

    Atlanta, Georgia

  • NuDirections Clinical Research, LLC (159)

    Atlanta, Georgia

  • iResearch Atlanta, LLC (146)

    Decatur, Georgia

  • Meridian Clinical Research, LLC (130)

    Savannah, Georgia

  • Josephson Wallack Munshower Neurology P.C. (114)

    Indianapolis, Indiana

  • Kosair Charities Pediatric Clinical Research Unit (120)

    Louisville, Kentucky

  • Michigan Head-Pain and Neurological Institute (103)

    Ann Arbor, Michigan

  • Mercy Research (116)

    St Louis, Missouri

  • Clinical Research Center of NJ (123)

    Voorhees Township, New Jersey

  • Dent Neurosciences Research Center (129)

    Amherst, New York

  • OnSite Clinical Solutions, LLC (155)

    Charlotte, North Carolina

  • Headache Wellness Center (Site 152)

    Greensboro, North Carolina

  • Raleigh Neurology Associates, PA (113)

    Raleigh, North Carolina

  • Akron Children's Hospital (site 139)

    Akron, Ohio

  • Cincinnati Children's Hospital (140)

    Cincinnati, Ohio

  • Preferred Primary Care Physicians, Inc. (115)

    Pittsburgh, Pennsylvania

  • Access Clinical Trials, Inc. (151)

    Nashville, Tennessee

  • Texas Neurology, P.A. (110)

    Dallas, Texas

  • Children's Medical Center Dallas (147)

    Dallas, Texas

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.